Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial

1 min read | July 09, 2024 10:05 PM EDT | By Sonal Goyal

Google News:

Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial — Image source: Company website

Recent News

Three Penny Stocks Benefiting From Growing Gold Exposure

Energy Fuels Growth Narrative Expands As Rare Earth Demand Rises

Apotex Health Valuation Debate Intensifies Following Market Debut

Advantage Energy Leadership Shift Sparks Fresh Market Attention

Make Kalkine Media
My Trusted Source

Highlights

The first patient in the Phase 1 bile tract cancer trial has been dosed.

The trial is expected to enrol 10 patients with bile tract cancer.

The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escalation trial is open and enrolling.

Imugene Limited (ASX: IMU) has dosed the first patient in its Phase 1 bile tract cancer (cholangiocarcinoma) trial. This trial marks the expansion of the MAST (Metastatic Advanced Solid Tumours) Phase 1 study, following promising responses in gastrointestinal cancers, particularly bile tract cancer, using VAXINIA, an oncolytic virus CF33.

The trial is being conducted at St. Vincent’s Hospital and aims to enrol 10 patients with bile tract cancer.

Triggered by the update, IMU shares jumped 7.8% to trade at AU$0.055 apiece at the time of writing on 10 July 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.